We have previously reported the cloning of cDNAs for a flavin-containing mono-oxygenase (FMO) 
INTRODUCTION
Metabolic oxidation of nitrogen-, sulphur-or phosphoruscontaining drugs, pesticides and other xenobiotics may be mediated by the flavin-containing mono-oxygenase (FMO; EC 1.14.13.8) system, the cytochrome P-450 mono-oxygenase system, or both. The relative contributions of each of these systems to the metabolism of such compounds is determined predominantly by the nucleophilic nature of the heteroatom, with 'soft' nucleophiles being preferentially oxygenated by FMOs (reviewed by Ziegler, 1980 Ziegler, , 1988 . FMO is known also to mediate the N-oxidation of the dietary derived amine, trimethylamine (TMA) (Hlavica & Kehl, 1977) . This biotransformation exhibits a genetic polymorphism in man (Al Waiz et al., 1987) , resulting in a small sub-population unable to effect TMA N-oxidation. Such individuals exhibit the unpleasant symptoms of the associated disorder trimethylaminuria, colloquially known as fish odour syndrome (Humbert et al., 1970; Shelley & Shelley, 1984) due to excretion of the malodorous free amine.
FMO has been purified and characterized from pig (Ziegler & Mitchell, 1972) , rat (Kimura et al., 1983) , mouse (Sabourin et al., 1984; Tynes et al., 1986) and rabbit (Tynes et al., 1986; Ozols, 1989) liver, mouse (Tynes et al., 1986) and rabbit (Williams et al., 1984; Tynes et al., 1986 ) lung, and mouse kidney (Venkatesh et al., 1991) . Observed differences in substrate specificities, relative M,s and immunochemical properties indicated that the 'hepatic' and 'pulmonary' FMOs represent different forms of the enzyme. This was subsequently confirmed by the isolation and sequencing of cDNA clones for the hepatic FMOs of pig and rabbit , and for the pulmonary FMO of rabbit . Ozols (1991) has reported the amino acid sequence of a second FMO purified from rabbit liver, designated rabbit liver form 2, which represents a third form of the enzyme that is distinct from both rabbit hepatic and pulmonary FMOs. Recently, Lawton et al. (1991) have investigated the substrate specificities of both rabbit hepatic and pulmonary FMOs by expressing their respective cDNAs in COS cells. Comparisons of kinetic parameters derived from these individually expressed enzymes with those derived from microsome-driven reactions indicate that both rabbit liver and lung each contain at least two forms of the enzyme.
We have recently described the isolation and characterization of cDNA clones that encode the human orthologue of pig and rabbit hepatic FMO , and have proposed the term FMO1 to describe the human protein and its orthologues in other mammalian species. We report here the isolation and characterization of cDNA clones that encode a second form of human FMO, which shown in Fig. 2 , and those for FMO1 amplification have been described previously . The olignonucleotides were synthesized on a PCR-MATE DNA synthesizer (model 391; Applied Biosystems). PCR conditions were as previously described . The reaction mixture was incubated (Thermal Rector; Hybaid) for 32 cycles at 94°C for 45 s, 56°C for 60 s and 72°C for 90 s, and then for an additional 5 min at 72 'C. Amplified product was extracted twice with phenol/chloroform (1: 1, v/v), ethanol-precipitated, resuspended in distilled water, and radiolabelled as described above. Prehybridization and hybridization conditions were as described previously . After hybridization, the membranes were washed in 2 x SSC (1 x SSC = 15 mM-sodium citrate/0. 15 M-NaCl, pH 7.0)/0.1 % SDS for 30 min at room temperature, in 0.1 x SSC/0.1 % SDS for 30 min at room temperature, and then at 50 'C in 0.1 x SSC/0. 1 % SDS for 15 min. Autoradiography was for 72 h at -78 'C with an intensifying screen.
1.4 kb partial-length cDNA encoding porcine FMO1 . The cDNA was radiolabelled by the oligonucleotide random primer method (Feinberg & Vogelstein, 1983) (Sanger et al., 1977) . One of the duplicate filters was then hybridized with a probe complementary to a region located within the 3' noncoding region of the cDNA encoding human FMO1 and the other with a probe complementary to the corresponding region of human FMO2. The probes were generated from cDNA clones by the PCR. The sequences and priming sites of the oligonucleotides used for FMO2 amplification are
Chromosomal localization
The hybrid cell lines used in this work (Table 1 ) have all been described previously, but many have subsequently been recloned and re-characterized. Genomic DNA was isolated as described previously (Edwards et al., 1985) . The sequences and priming sites of the two 20-mer oligonucleotides used to prime the PCR are indicated in Fig. 2 . Amplification reactions were performed using either 1 jug of human or rodent cell DNA or 2 ,ug of somatic cell hybrid DNA. DNA samples were amplified using the DNA polymerase from Thermus thermophilus (TET/Z; Bioline). Reaction conditions were as described previously , except that the amplification was for 35 cycles of 90°C for 1 min, 50°C for 1 min and 70°C for 1 min. PCR products were analysed on a 2.5 % agarose gel.
RESULTS
An initial screen of 2.5 x 105 plaques of an adult human liver cDNA library with a 1.4 kb cDNA insert encoding pig FMO1 yielded 10 positive clones. One of these, which gave a strong hybridization signal, contained a partial-length cDNA insert that encoded human FMO1 and has been described previously . The remaining nine clones gave much weaker hybridization signals. One of these, designated 2A1, contained a 1.4 kb insert ( Fig. 1 ) that encoded a polypeptide, the amino acid sequence of which was approx. 50 % identical with that of human FMO1. Restriction mapping and partial sequencing indicated that the other eight clones contained overlapping cDNAs (results not shown). To obtain longer cDNAs for this polypeptide, 4 x 105 plaques of the library were re-screened at higher stringency with the insert of clone 2A1. Fifteen additional clones were isolated, the largest of which (clone 13W) contained a cDNA insert of over 2.1 kb (Fig. 1 ).
Restriction mapping revealed that the other clones contained shorter versions of the same cDNA (results not shown).
A full-length cDNA sequence was assembled from clones 2A1 and 13W as indicated in Fig. 1 , and, together with the amino acid sequence deduced from it, is shown in Fig. 2 1990; 1991; Dolphin et al., 1991) are present between residues codons. Furthermore, the ATG was followed closely by an in-9-14 and 191-196 respectively (Fig. 2) . The polypeptide contains frame termination codon (bases 70-72). In contrast, the sequence no Asn-Xaa-(Thr/Ser) potential N-glycosylation sites.
surrounding the proposed initiation codon, ACCATGG, is the
The corresponding mRNA has a long 5' leader sequence that most favourable for translational initiation (Kozak, 1987) .
contains a single 'upstream' ATG at positions 55-57 (Fig. 2 ). Fig. 3 shows an alignment of the amino acid sequence of
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--DYIAYMDDIAACIGTKPSIPLLFLKDPRLAWEVFFGPCTPYQYRLMGPGKWDGARNAILTQWDRTLKPLK 429 QTN**D*L*EL*LE**A**DLVSFLF***K**VKLY****NS*****V***Q*E******F**KQ*I***** 429 QS***T*I*ELLTY*NA**NLFSML*T**H**LT******S***F**T*****E******M******F*VI* 429 QT***N***EL*SF**V*LN**W***T*****L*******S***F**V*****P***Q********S***M* 499 TRIVPDSSKPASMSHYLKAWGAPVLLASLLLICKSSLFLKLVRDKLQDRMSPYLVSLWRG 501 **TLKA**N-FPV*FL**FL*LFA*VLAF*FQLQWF 501 A*V*QE*PS*--FESF**VFSFLA**VAIF**FL 501 **A*GHLQ***LF*PE*WLLAIA***IAAV*VF Fig. 4 the hydropathy profile of human FMO2, determined by the method of Kyte & Doolittle (1982) using a window size of nine residues, is compared with those of rabbit pulmonary FMO , human FMO1 and rabbit liver FMO form 2 (Ozols, 1991 identification of membrane-spanning regions, only the sequence between residues 517 and 531 has a mean hydropathy value of greater than 1.6, which is indicative of a potential membranespanning segment (results not shown). In other FMOs this hydrophobic region is situated at the extreme C-terminus of the polypeptide, but in human FMO2 it is followed by a short stretch of hydrophilic residues that are predicted, by the methods of both Chou & Fasman (1978) and Gamier et al. (1978) , to adopt an a-helical secondary structure (results not shown). Although the cDNA clones encoding FMO2 were isolated from an adult human liver library, Northern blot hybridization failed to detect the corresponding mRNA in total RNA isolated from four different adult livers (results not shown). The mRNA was also undetectable in total RNA isolated from adult kidney and lung, and from foetal liver. Human genomic DNA was analysed by Southern blot hybridization using probes derived from the 3' non-coding regions of FMO1 and FMO2 cDNAs (Fig. 5) . The probes comprise DNA sequences that are contained within single exons of the corresponding genes ( Fig. 6 ; Dolphin et al., 1991) . Both cDNA probes hybridized to single fragments in genomic DNA digested by EcoRI, BamHI or PstI (Fig. 5) . The FMO1 cDNA probe Vol. 287 Fig. 2 ) direct the selective amplification from human genomic DNA of a 172 bp fragment (Fig. 6 , track E) corresponding to a sequence located entirely within the 3' non-coding region of the cloned cDNA. No amplification product was obtained from DNA prepared from mouse, rat or hamster donor cell lines (Fig. 6, tracks A-D) . Analysis of DNA isolated from 16 human-rodent somatic cell hybrids showed that the 172-bp fragment was amplified only from DNA samples isolated from hybrids that contained human chromosome1 (Fig. 6 and Table 1 ). The results shown in Table  1 demonstrate complete correlation between the amplified DNA product (indicative of the human FMO2 gene) and the presence of human chromosome 1. There are at least four cases of discordance for each of the other human chromosomes.
DISCUSSION
We have previously isolated cDNA clones that encode the human orthologue of rabbit and pig hepatic FMOs (designated FMO1) . The primary sequence of human FMO1 displays 86-88% similarity to its animal orthologues, but less than 60% similarity to two non-orthologous forms of FMO, namely rabbit pulmonary FMO (Lawtonet al., 1990) and rabbit liver FMO form 2 (Ozols, 1991) . We now report the isolation of cloned cDNAs that encode a second form of human FMO, which we have designated FMO2. The degree of primary sequence similarity between human FMO2 and other forms of the enzyme (between 51 and 53%) indicates that it is not orthologous to any of these and thus represents a fourth, distinct, member of the mammalian FMO family.
A comparison of representatives of the four distinct forms of mammalian FMOs identified to date (Fig. 3) reveals that the degree of sequence identity between these proteins is not uniform throughout the polypeptide chain. The relatively high percentage of residues between positions 1 and 230, and between 450 and 500, that are conserved among all four proteins indicates important structural and/or functional roles for these regions, the former of which contains the putative FAD-and NADPbinding sites. Although the region between residues 230 and 450 is less conserved among different FMOs, it contains sections which are highly conserved among FMO1 orthologues , suggesting that sequences within this region may be responsible for inter-form differences in FMO function.
At codons 531 and 532, a position that corresponds very closely to the end of other forms of FMO, human FMO2 has the sequence TGTAAA (Fig. 2) . Thus the extra residues at the Cterminus of the polypeptide may have resulted from a point mutation in an ancestral FMO2 gene that either changed the third base of a TGA stop codon at position 531 or altered the reading frame of a TAA stop codon, in either case allowing translation to continue until the next in-frame termination codon at position 559. Korsmeyer et al. (1990) have demonstrated that pig FMOI is glycosylated at one or both of its two possible Asn-Xaa-Thr/Ser N-glycosylation sites. Although the glycosylation status of other FMOs has not been determined, all FMO sequences reported to date contain at least one such potential oligosaccharide acceptor site. In contrast, human FMO2 contains no such sites, indicating that it is not subject to modification by N-glycosylation. Peptide sequencing has revealed that the initiation methionine residue is absent from the mature forms of pig (Guan et al., 1990) and rabbit (Ozols, 1990) FMO1 and from rabbit liver FMO form 2 (Ozols, 1991) . Although examination of sequences deduced from cDNAs does not allow conclusions concerning the nature of possible N-terminal modifications of the mature protein, it is of interest that in the deduced amino acid sequence of human FMO2, as in those of human FMO1 and rabbit pulmonary FMO , the initiation methionine is followed by alanine, a residue that appears to promote the removal of methionine during protein maturation (Flinta et al., 1986) .
The hydrophobic stretch of amino acid residues at the Nterminus of human FMO2 has some similarities to a signal peptide sequence. However, the presence of a putative FADbinding site within this region suggests that it may not function as a membrane-insertion domain. Indeed, the only hydrophobic region of the protein that fully meets the criteria of Kyte & Doolittle (1982) for a potential membrane-spanning sequence is that located near the C-terminus of the protein. Despite the fact that FMOs exhibit very little sequence identity within this region, the hydrophobic nature of the region has been well conserved and thus it is likely that this domain serves to anchor FMOs in the membranes of the endoplasmic reticulum.
The results of Northern blot hybridization demonstrate that the human FMO2 gene is not expressed at a high level in any of the tissues associated with FMO activities in experimental animals, namely liver, lung and kidney. However, as we were able to isolate cDNA clones for human FMO2 from a library constructed from adultliver RNA, the gene must be expressed in this tissue, albeit at a low level. The frequency of independent FMO2 clones in the library (approx. 1 in 2 x 104) suggests that the abundance of the corresponding mRNA, although very low, is far higher than that of mRNA encoding human FMO1 (which has a cDNA clone frequency of 1 in 7.5 x 105) . In contrast to FMO1, FMO2 is not expressed at a high level in foetal liver.
At present it is unclear which form(s) of human FMO may be responsible for the N-oxidation of TMA and hence may be involved in the metabolic disorder trimethylaminuria. In vitro studies to elucidate the relative contributions of human FMO1 and FMO2 to TMA metabolism may help to answer this question.
We have demonstrated that human FMO1 and FMO2 are each encoded by single genes, and have mapped the FMO2 gene (which we have designated FM02) to human chromosome 1. The FMO1 gene is also located on this chromosome , and we have evidence that both the FMO1 and FMO2 genes are situated on the long arm of chromosome 1 , raising the possibility that the genes form part of a gene cluster.
Comparison of the sequences of orthologous FMOs indicates that, for these proteins, the time required to establish a 1 % difference in amino acid sequence, known as the unit evolutionary period, is about 6 million years . Based on this rate of evolution and the degree of sequence similarity between non-orthologous forms, it would appear that the known members of the FMO gene family arose from gene duplication events that occurred some 250-300 million years ago.
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